Unmet needs in the treatment of schizophrenia: The role of aripiprazole;Bisogni irrisolti nel trattamento della schizofrenia: Ruolo di aripiprazolo

Italian Journal of Psychopathology

Volumn 14, Issue 1, 2008, Pages 88-104

  Allochis, G ^a   Cavallaro, R ^b   Milano, W ^c   Monteleone, Palmiero ^d   Paroli, A ^e   Rossi, A ^f  

^a ASO Maggiore della Carita   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^c ASL Napoli 1   (Italy)

^d SECOND UNIVERSITY OF NAPLES   (Italy)

^e UNIVERSITY OF BRESCIA   (Italy)

^f UNIVERSITY OF L'AQUILA   (Italy)

Author keywords

Antipsychotics; Aripiprazole; Schizophrenia; Unmet needs

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; OLANZAPINE; PERPHENAZINE; PLACEBO; QUETIAPINE; RISPERIDONE;

AKATHISIA; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITION; DIABETES MELLITUS; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; ENDOCRINOLOGY; EXPERIENCE; EXTRAPYRAMIDAL SYMPTOM; HUMAN; HYPERPROLACTINEMIA; INCIDENCE; INSOMNIA; MEDICAL RESEARCH; METABOLIC DISORDER; NEUROLEPTIC MALIGNANT SYNDROME; OBESITY; PATIENT COMPLIANCE; PSYCHIATRIST; QUALITY OF LIFE; SCHIZOPHRENIA; SCIENTIFIC LITERATURE; SEXUAL DYSFUNCTION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 44449169476     PISSN: 15921107     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (86)

1. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001;158:518-26.
2. Geddes J, Freemantle N, Harrison P, Bebbington P; National Schizophrenia Guideline Development Group. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000;321:1371-6.
3. Geddes J, Harrison P, Freemantle N. New generation versus conventional antipsychotics [letter]. Lancet 2003;362:404.
4. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003;361:1581-9.
5. Davis JM, Chen N, Glick ID. A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003;60:553-64.
6. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
7. El-Sayeh HG, Morganti C. Aripiprazole for schizophrenia. Cochrane Database Syst Rev. 2004;(2):CD004578.
8. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, et al. Mechanism of action of aripiprazole predicts clinical efficacy and favourable side effects. J Psychopharmacol 2004;18:375-83.
9. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63:763-71.
10. McEvoy JP, Daniel DG, Carson WH Jr, McQuade RD, Marcus RN. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J Psychiatr Res 2007;41:895-905.
11. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs. placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90.
12. Pigott TA, Carson WH, Saha AR, Torbeyns AF, Stock EG, Ingenito GG. Aripiprazole for the prevention of relapse in stabilized patients with chronic schizophrenia: a placebo-controlled 26-week study. J Clin Psychiatry 2003;64:1048-56.
13. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, et al. Efficacy and safety of aripiprazole vs. aloperidolo for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6:325-37.
14. Awad AG, Hogan TP, Voruganti LN, Heslegrave RJ. Patients' subjective experiences on antipsychotic medication: implication for outcome and quality of life. Int Clin Psychopharmacol 1995;10(Suppl.3):123-32.
15. Gerlach J. The continuing problem of extrapyramidal symptoms: strategies for avoidance and effective treatment. J Clin Psychiatry 1999;60(Suppl.23):20-4.
16. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995;21:419-29.
17. Casey DE. Implications of the CATIE trial on treatment: extrapyramidal symptoms. CNS Spectr 2006;11(Suppl.7):25-31.
18. Leucht S, Pitschel-Walz G, Abraham D, Kissling W. Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr Res 1999;35:51-68.
19. Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second generation antipsychotics: a systematic review of one year studies. Am J Psychiatry 2004;161:414-25.
20. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61:123-36.
21. El-Sayeh HG, Morganti C, Adams CE. Aripiprazole for schizophrenia. Br J Psychiatry 2006;189:102-8.
22. Miller del D, Eudicone JM, Pikalov A, Kim E. Comparative assessment of the incidence and severity of tardive dyskinesia in patients receiving aripiprazole or haloperidol for the treatment of schizophrenia: a post hoc analysis. J Clin Psychiatry 2007;68:1901-6.
23. Lykouras L, Rizos E, Gournellis R. Aripiprazole in the treatment of tardive dyskinesia induced by other atypical antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1535-6.
24. Kane JM, Smith JM. Tardive dyskinesia and risk factor, 1959-1979. Arch Gen Psychiatry 1982;39:473-81.
25. Kane JM, Jeste DV, Barnes TRE, Casey DE, Cole JO, Davis JM, et al. Tardive dyskinesia: a task force report of the American Psychiatric Association. Arlington (VA): American Psychiatric Association 1992.
26. Glazer WM, Morgenstern H, Doucette JT. Predicting the long term risk of tardive dyskinesia in outpatients maintained on neuroleptic medication. J Clin Psychiatry 1993;54:133-9.
27. Marder SR, Miebach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994;151:825-35.
28. Peuskens J. Risperidone in the treatment of patients with chronic schizophrenia: a multi-national, multi-centre, double-blind, parallel-group study versus haloperidol. Br J Psychiatry 1995;166:712-26.
29. Gerlach J. Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria. Ann Clin Psych 2002;14:47-57.
30. Aravantis LA, Miller BG. The Seroquel trial 13 study-group. Multiple fixed doses of Seroquel in patients with acute exacerbations of schizophrenia: a comparison with haloperidol and placebo. Biol Psych 1997;42:233-46.
31. Spivak B, Mester R, Abesgaus J, Wittenberg N, Adlersberg S, Gonen N, et al. Clozapine treatment for neuroleptic-induced tardive dyskinesia, parkinsonism, and chronic akathisia in schizophrenic patients. J Clin Psychiatry 1997;58:318-22.
32. Kinon BJ, Jeste DV, Kollack-Walker S, Stauffer V, Liu-Seifert H. Olanzapine treatment for tardive dyskinesia in schizophrenia patients: a prospective clinical trial with patients randomized to blinded dose reduction periods. Prog Neuropsychopharmacol Biol Psychiatry 2004;28:985-96.
33. Bai YM, Yu SC, Lin CC. Risperidone for severe tardive dyskinesia: a 12-week randomized, double-blind, placebo-controlled study. J Clin Psychiatry 2003;64:1342-8.
34. Khan M, Farver D. Recognition, assessment, and management of neuroleptic malignant syndrome. SDJ Med 2000;53:395-400.
35. Ananth J, Parameswaran S, Gunatilake S, Burgoyne K, Sidhom T. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004;65:464-70.
36. Spalding S, Alessi NE, Radwan K. Aripiprazole and atypical neuroleptic malignant syndrome. J Am Acad Child Adolesc Psychiatry 2004;43:1457-8.
37. Strawn JR. Aripiprazole and the neuroleptic malignant syndrome. Schizophr Res 2006;85:298-9.
38. Molina D, Tingle LE, Lu X. Aripiprazole as the causative agent of neuroleptic malignant syndrome: a case report. Prim Care Companion J Clin Psychiatry 2007;9:148-50.
39. Evcimen H, Alici-Evcimen Y, Basil B, Mania I, Mathews M, Gorman JM. Neuroleptic malignant syndrome induced by low dose aripiprazole in first episode psychosis. J Psychiatr Pract 2007;13:117-9.
40. Newcomer JW. Metabolic considerations in the use of antipsychotic medications: a review of recent evidence. J Clin Psychiatry 2007;68(Suppl.1):20-7.
41. Henderson DC. Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 2005 ;66(Suppl.6):11-20.
42. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologist, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601.
43. Allison D, Fontaine K. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-20.
44. Wirshing AD. Schizophrenia and obesity: impact of antipsychotic medications. J Clin Psychiatry 2004;65(Suppl. 18):13-26.
45. Taylor DM, McAskill R. Atypical antipsychotic and weight gain a systematic review. Acta Psychiat Scand 2000;101:416-32.
46. Melkerson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics. Drugs 2004;64:701-23.
47. Tsapakis EM, Travis MJ. Handbook of schizophrenia. London: Current Medicine Group 2005.
48. Blin O, Micallef J. Antipsychotic associated weight gain and clinical outcome parameters. J Clin Psychiatry 2001;62(Suppl.7):11-21.
49. Sussman N. Review of atypical antipsychotic and weight gain. J Clin Psychiatry 2001;62(Suppl.23):292-3.
50. Klett CJ, Caffey EM Jr. Weight changes during treatment with phenothiazine derivatives. J Neuropsychiatr 1960;2:102-8.
51. Amdisem A. Drug-produced obesity: experiences with chlorpromazine, perphenazine and clopenthixol. Dan Med Bull 1964;11:182-9.
52. Planansky K. Changes in weight in patients receiving a tranquilizing drug. Psychiatr Quart 1958;32:289-303.
53. Wetterling T. Bodyweight gain with atypical antipsychotic: a comparative review. Drug Safety 2001;24:59-73.
54. Zinnerman U, Kraus T. Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients. J Psychiatr Res 2003;37:193-220.
55. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001;62(Suppl.7):27-34.
56. Nasrallah H. A review of the effect of atypical antipsychotic on weight. Psychoneuroendocrinology 2003;28:83-96.
57. Grundy SM, Cleeman JI, Merz CN, Brewer HB Jr, Clark LT, Hunninghake DB, et al.; Coordinating Committee of the National Cholesterol Education Program. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. J Am Coll Cardiol 2004;44:720-32.
58. Allison BD, Casey D. Antipsychotic induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(Suppl.7):22-31.
59. McQuade RD, Stock E, Marcus R, Jody D, Gharbia NA, Vanveggel S, et al. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study. J Clin Psychiatry 2004;65(Suppl.18):47-56.
60. Haddad P, Scharma SG. Adverse effects of atypical antipsychotics. CNS Drugs 2007;21:911-36.
61. De Hert M, van Winkel R, Van Eyck D, Hanssens L, Wampers M, Scheen A, et al. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the mental illness: a cross-sectional study. Clin Pract Epidemol Ment Health 2006;2:14.
62. Henderson DC. Schizophrenia and comorbid metabolic disorders. J Clin Psychiatry 2005;66(Suppl.6):11-20.
63. Nasrallah HA. Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles. Mol Psychiatry 2007:10:1-9.
64. Ader M, Kim SP, Catalano KJ, lonut V, Hucking K, Richey JM, et al. Metabolic dysregulation with atypical antipsychotics occurs in the absence of underlying disease. A placebo-controlled study of olanzapine and risperidone in dogs. Diabetes 2005;54:862-71.
65. De Fronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;237:E214-23.
66. L'Italien GJ, Casey DE, Kan HJ, Carson WH, Marcus RN. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo. J Clin Psychiatry 2007;68:1510-6.
67. Chrzanowski WK, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology 2006;189:259-66.
68. Lee BH. Using aripiprazole to resolve antipsychotic-induced syntomatic hyperprolactinemia: a pilot study. Prog Neuropsycopharmacol Biol Psychiatry 2006;30:714-7.
69. Kerwin R, Millet B, Herman E, Banki CM, Lublin H, Pans M, et al. A multicentre, randomized, naturalistic, open-label study between aripiprazole and standard of care in the management of community-treated schizophrenic patients. Schizophrenia Trial of Aripiprazole: (STAR) study. Eur Psychiatry 2007;22:433-43.
70. Spurling RD, Lamberti JS, Olsen D, Tu X, Tang W. Changes in metabolic parameters with switching to aripiprazole from another second-generation antipsychotic: a retrospective chart review. J Clin Psychiatry 2007;68:406-9.
71. Casey DE. Long-term treatment with aripripazole: effects on plasma lipid levels and glicemic control. Int J Neuropsychopharmacol 2004;7(Suppl.1):418.
72. Marder SR, Essock SM. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004;161:1334-49.
73. Kurzthaler I, Fleischacker W. The clinical implications of weight gain in schizophrenia. J Clin Psychiatry 2001;62(Suppl.7):32-7.
74. Killian JG, Kerr K, Lawrence C, Celermajer DS. Myocarditis and cardiomyopathy associated with clozapine. Lancet 1999;354:1841-5.
75. Warner B, Alphs L, Schaedelin J, Koestler T. Clozapine and sudden death. Lancet 2000;355:842.
76. Wallace M. Real progress: the patient's perspective. Int Clin Psychopharmacol 2001;16(Suppl.2):1-4.
77. Knegtering R, Castelein S, Bous H, Van Der Linde J, Bruggeman R, Kluiter H, et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 2004;24:56-61.
78. Steven GP. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60:681-90.
79. Shim JC, Shin JG, Kelly DL, Jung DU, Seo YS, Liu KH, et al. Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am J Psychiatry 2007;164:1404-10.
80. Lee BH. Using aripiprazole to resolve antipsychotic-induced syntomatic hyperprolactinemia: a pilot study. Prog Neuropsycopharmacol Biol Psychiatry 2006;30:714-7.
81. Beasley CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997;58(Suppl.l0):13-7.
82. Kane JM, Meltzer HY, Carson WH Jr, McQuade RD, Marcus RN, Sanchez R; Aripiprazole Study Group. Aripiprazole for treatment-resistant schizophrenia: results of a multicenter, randomized, double-blind, comparison study versus perphenazine. J Clin Psychiatry 2007;68:213-23.
83. Tandon R, Marcus RN, Stock EG, Riera LC, Kostic D, Pans M, et al. A prospective, multicenter, randomized, parallel-group, open-label study of aripiprazole in the management of patients with schizophrenia or schizoaffective disorder in general psychiatric practice: Broad Effectiveness Trial With Aripiprazole (BETA). Schizophr Res 2006;84:77-89.
84. Wolf J, Janssen F, Lublin H, Salokangas RK, Allain H, Smeraldi E, et al. A prospective, multicentre, open-label study of aripiprazole in the management of patients with schizophrenia in psychiatric practice in Europe: Broad Effectiveness Trial with Aripiprazole in Europe (EU-BETA). Curr Med Res Opin 2007;23:2313-23.
85. Wlodzimierz K, Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;189:259-66.
86. Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine 1. Psychopharmacology (Berl) 2006;187:312-20.